Drive diabetes patient compliance with clinically proven and clinically relevant HbA1c1, Albumin, Creatinine, and Albumin-to-Creatinine (A:C) Ratio tests on the new DCA Vantage™ Analyzer. Simple enough to use in your office lab, and yet powerful enough to deliver lab-quality performance in point-of-care coordinated settings. It's the flexibility, ease and precision you've been looking for, in every setting.
Drive Glycemic Control Compliance2 and Detect Kidney Disease, Earlier
The DCA Vantage Analyzer is a point-of-care immunoassay analyzer for diabetes management. It provides precise and accurate quantitative test results for HbA1c in whole blood during the patient visit to help improve decision making3,4 With a single urine sample, the analyzer also provides quantitative test results for low levels of Albumin,
Creatinine and A:C Ratio in the physician office or clinic.
The analyzer leverages the robust technology that delivers the proven performance of the DCA HbA1c and DCA Microalbumin/Creatinine tests highlighted in over 100 clinical articles. Provide the clinical confidence you and your patients deserve by adopting the new DCA Vantage system which uses a technology with a proven track record and is used by three out of four physicians who perform HbA1c testing in their office.
This simple, easy to use analyzer improves productivity by providing test results during patient visit in 6 to 7 minutes, reducing time needed for patient follow-up. There is no sample or reagent preparation required. Simply load test cartridge with sample onto system and walk away and spend more time with patients. The analyzer automatically generates test results and provides a printed record that can be affixed to the patient file and/or uploaded to a network or LIS/HIS.
We value your feedback! Please take this 5 minute survey
Survey
1, 2, 3, 4 See references below.
References
1. Immediate feedback of HbA1c levels improves glycemic control in Type 1 and insulin-treated
Type 2 diabetic patients. Cagliero E, Levina DV, Nathan DM. Diabetes Care 1999;22:1785-9.
2. Near patient testing in diabetes clinics: appraising the costs and outcomes. Grieve R,
Beech R, Vincent J, Mazurkiewicz J. Health Technolol. Assess. 1999;3(15):1-74.
3. Diabetes in urban African-Americans. XVII. Availability of rapid HbA1c measurements
enhances clinical decision-making. Thaler LM, Ziemer DC, Gallina DL, Cook CB, Dunbar VG,
Phillips LS, El-Kebbi IM. Diabetes Care 1999;22:1415-21
4. Rapid A1c availability improves clinical decision-making in an urban primary care clinic.
Miller CD, Barnes CS, Phillips LS, Ziemer DC, Gallina DL, Cook CB, et al. Diabetes Care 2003;
26:1158-63.